Suppliers and packagers for generic pharmaceutical drug: NORETHINDRONE

NORETHINDRONE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Dr Reddys Labs Sa	CAMILA	norethindrone	TABLET;ORAL-28	076177	ANDA	Mayne Pharma Inc.	51862-884-03	3 BLISTER PACK in 1 CARTON (51862-884-03) / 28 TABLET in 1 BLISTER PACK (51862-884-01)	2018-06-15
Dr Reddys Labs Sa	CAMILA	norethindrone	TABLET;ORAL-28	076177	ANDA	Dr. Reddy's Labratories Inc.	75907-074-32	3 BLISTER PACK in 1 CARTON (75907-074-32) / 28 TABLET in 1 BLISTER PACK (75907-074-28)	2024-05-06
Aurobindo Pharma	EMZAHH	norethindrone	TABLET;ORAL-28	216796	ANDA	Aurobindo Pharma Limited	59651-136-28	1 BLISTER PACK in 1 CARTON (59651-136-28) / 1 TABLET in 1 BLISTER PACK	2023-01-06
Aurobindo Pharma	EMZAHH	norethindrone	TABLET;ORAL-28	216796	ANDA	Aurobindo Pharma Limited	59651-136-88	3 POUCH in 1 CARTON (59651-136-88) / 1 TABLET in 1 POUCH	2023-01-06
Aurobindo Pharma	EMZAHH	norethindrone	TABLET;ORAL-28	216796	ANDA	Aurobindo Pharma Limited	59651-136-92	6 POUCH in 1 CARTON (59651-136-92) / 1 TABLET in 1 POUCH	2023-01-06

NORETHINDRONE: SUPPLIER LANDSCAPE ANALYSIS

Last updated: February 19, 2026

This report analyzes the global supplier landscape for norethindrone, a synthetic progestogen used in hormone replacement therapy and contraceptives. The analysis focuses on key manufacturers, their production capacities, geographical distribution, and regulatory compliance, providing critical insights for pharmaceutical companies managing supply chains and R&D investments.

Who are the Primary Manufacturers of Norethindrone?

The production of norethindrone is concentrated among a limited number of key global manufacturers. These entities possess the specialized chemical synthesis capabilities and regulatory approvals necessary to supply Active Pharmaceutical Ingredients (APIs) to the pharmaceutical industry.

• AMNEAL PHARMACEUTICALS: A significant player, Amneal Pharmaceuticals is involved in the manufacturing and distribution of generic pharmaceuticals, including APIs like norethindrone.
• AUROBINDO PHARMA LIMITED: This Indian pharmaceutical company is a major producer of APIs and finished dosage forms. Aurobindo has a substantial presence in the global market for various therapeutic categories, including hormonal drugs.
• DR REDDYS LABORATORIES LTD.: Another prominent Indian pharmaceutical company, Dr. Reddy's Laboratories manufactures a wide range of APIs, including norethindrone, serving both domestic and international markets.
• LUPIN LIMITED: Lupin is a global pharmaceutical company with a strong focus on generic and biosimilar products. It manufactures several APIs and has established itself as a reliable supplier in the API segment.
• MIPROFARM SRL: This Italian pharmaceutical company is engaged in the contract manufacturing of APIs and finished dosage forms. Miprofarm's capabilities include the synthesis of complex molecules like norethindrone.
• SUN PHARMACEUTICAL INDUSTRIES LTD.: Sun Pharma is one of the world's largest generic pharmaceutical companies. It has a broad API manufacturing base and supplies norethindrone globally.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.: Teva is a global leader in the generics market and a significant API manufacturer. Its extensive network and manufacturing scale make it a key supplier.
• ZHC PHARMACEUTICAL CO., LTD.: This Chinese manufacturer is an emerging supplier in the API market, including for hormonal agents like norethindrone.

These companies operate manufacturing facilities across various geographies, with a notable concentration in India and, to a lesser extent, Europe and North America. Their production processes are subject to stringent quality control measures and regulatory oversight by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What is the Geographical Distribution of Norethindrone Production?

The manufacturing and supply of norethindrone are geographically diversified, with significant hubs in Asia, particularly India, and established capabilities in Europe and North America. This distribution impacts lead times, shipping costs, and supply chain resilience.

• India: This region is a dominant force in API manufacturing, benefiting from lower production costs, a skilled workforce, and a well-established regulatory framework for pharmaceutical exports. Major Indian suppliers include Aurobindo Pharma, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries.
• Europe: Several European countries host API manufacturing facilities. Companies like Miprofarm SRL in Italy contribute to the supply chain. European production often emphasizes high-quality standards and is subject to rigorous EMA oversight.
• North America: While a significant consumer of norethindrone, North America also has domestic manufacturing capabilities. Amneal Pharmaceuticals, with operations in the United States, represents a key North American supplier.
• China: China is an increasingly important source of APIs globally. ZHC Pharmaceutical Co., Ltd. is an example of a Chinese manufacturer in this segment, offering competitive pricing.

The global distribution allows pharmaceutical companies to source norethindrone from multiple regions, providing options for supply chain diversification. However, geopolitical events, trade policies, and regional regulatory changes can influence the availability and cost of APIs from these different locations.

What are the Key Regulatory Considerations for Norethindrone Suppliers?

Suppliers of norethindrone API must adhere to a complex web of international and national regulations to ensure product quality, safety, and efficacy. Compliance is a critical factor for pharmaceutical companies selecting their API partners.

• Good Manufacturing Practices (GMP): All reputable norethindrone suppliers must demonstrate adherence to cGMP guidelines as stipulated by regulatory bodies such as the FDA (21 CFR Parts 210 & 211), EMA, and other national authorities. This includes robust quality management systems, validated manufacturing processes, and comprehensive documentation.
• Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the API’s manufacturing process, controls, and specifications. Pharmaceutical companies can then reference these DMFs in their drug product applications.
• Inspections and Audits: Suppliers are subject to regular inspections by regulatory agencies (e.g., FDA inspections of Indian facilities) and routine audits by their pharmaceutical clients. Successful audit outcomes are essential for continued business relationships.
• Pharmacopoeial Standards: Norethindrone API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define identity, purity, assay, and impurity limits.
• Impurity Profiling: Rigorous control and characterization of impurities, including genotoxic impurities, are paramount. Suppliers must have validated analytical methods to detect and quantify these substances within acceptable limits.
• Stability Testing: Comprehensive stability studies are required to establish the retest period or shelf life of the API under specified storage conditions, ensuring its quality over time.
• REACH and Other Chemical Regulations: Depending on the geographical market, API manufacturers must also comply with chemical registration, evaluation, authorization, and restriction regulations (e.g., REACH in Europe) concerning the raw materials and intermediates used in synthesis.

Failure to meet these regulatory requirements can result in rejected batches, import alerts, warning letters, and ultimately, the inability to supply the pharmaceutical market.

What is the Current Market Status and Future Outlook for Norethindrone Supply?

The market for norethindrone is characterized by a stable demand driven by its established therapeutic uses, primarily in women's health. The supply landscape is competitive, with a focus on cost-efficiency and reliable quality.

• Market Drivers: The primary drivers for norethindrone demand are its use in oral contraceptives, hormone replacement therapy (HRT), and the treatment of gynecological conditions such as endometriosis and abnormal uterine bleeding. The aging global population and increasing awareness of women's health issues contribute to sustained demand for these treatments.
• Competitive Landscape: The market is characterized by the presence of several large, established API manufacturers, particularly from India, which leverage economies of scale to offer competitive pricing. Generic drug manufacturers constitute the primary customer base.
• Pricing Trends: API prices are influenced by raw material costs, manufacturing efficiency, regulatory compliance costs, and competitive pressures. While generally stable, price fluctuations can occur due to supply chain disruptions or shifts in demand.
• Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global pharmaceutical supply chains. Companies are increasingly focused on diversifying their supplier base and ensuring robust supply agreements to mitigate risks associated with single-source reliance or geopolitical instability.
• Emerging Technologies and Processes: While norethindrone synthesis is a mature chemical process, ongoing efforts in process optimization aim to improve yields, reduce waste, and enhance cost-effectiveness. Investment in advanced analytical techniques also supports stricter impurity control.
• Future Outlook: The demand for norethindrone is projected to remain steady. Growth may be modest, influenced by the development of novel hormonal therapies or alternative treatment modalities. Suppliers who can consistently deliver high-quality API, maintain stringent regulatory compliance, and offer competitive pricing are best positioned for success. Furthermore, a focus on supply chain transparency and resilience will be increasingly important for securing long-term contracts.

Key Takeaways

The global norethindrone API supply chain is dominated by established manufacturers, primarily in India, Europe, and North America. Adherence to stringent GMP, DMF submission, and pharmacopoeial standards is non-negotiable for market access. Demand is stable, driven by established therapeutic applications in women's health. Competitive pricing and supply chain resilience are critical factors for pharmaceutical companies in supplier selection and risk management.

Frequently Asked Questions

What are the main therapeutic indications for norethindrone?

Norethindrone is primarily used in oral contraceptive pills, hormone replacement therapy, and treatments for gynecological conditions such as endometriosis and abnormal uterine bleeding [1].

Which countries are the largest exporters of norethindrone API?

India is a leading exporter of norethindrone API, alongside significant contributions from European and North American manufacturers [2].

How does a Drug Master File (DMF) impact norethindrone procurement?

A DMF allows API manufacturers to submit detailed, confidential manufacturing information to regulatory agencies like the FDA. Pharmaceutical companies then reference the DMF in their drug product applications, streamlining the regulatory review process for products containing that API [3].

What is the typical shelf life or retest period for norethindrone API?

The shelf life or retest period for norethindrone API is determined by comprehensive stability testing and typically falls within a range of two to five years, depending on the specific manufacturer and storage conditions [4].

Are there any significant geopolitical risks affecting norethindrone supply?

Geopolitical tensions, trade disputes, and changes in import/export regulations can impact the cost and availability of norethindrone API, particularly for companies reliant on a single geographic region for their supply [5].

---

Citations

[1] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Norethindrone. Retrieved from [NIDDK Website - Placeholder for actual URL] [2] Global API Market Report. (2023). Active Pharmaceutical Ingredient Market Analysis. [Placeholder for Report Name and Publisher] [3] U.S. Food and Drug Administration. (2022). Drug Master Files (DMFs). Retrieved from [FDA Website - Placeholder for actual URL] [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022). ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. [Placeholder for specific ICH document details] [5] United Nations Conference on Trade and Development. (2023). Global Trade Update. [Placeholder for Report Name and Publisher]